… Given the limitation in long-term therapeutic efficacy of current BRAF V600 inhibitors, … of
MEK inhibition in treating BRAF mutant melanoma. In addition, combination BRAF/MEK inhibitor …

… In summary, this study shows that combined therapy of BRAF and MEK inhibitors may
moderately improve the overall response, PFS, and OS, although it may increase the incidence of …

… I study of a MEK inhibitor (CI-1040) was carried out by LoRusso and colleagues, 34
numerous clinical studies have been conducted to evaluate various MEK inhibitors. In particular, …

… MEK has not been identified as an oncogene product, MEK … Pivotal cellular studies carried
out with the MEK inhibitor … , these studies have shown that MEK inhibition not only impairs …

… area of great interest, especially drugs targeting the inhibition of MEK. In vitro and clinical
studies have shown promise for certain MEK inhibitors (MEKi) , and MEKi have become the …

… pathway in carcinogenesis and as a novel therapeutic oncogenic target. Particular attention
is paid to MEK inhibitors (MEKi) as promising therapeutic agents. We describe the clinical …

… MEK-targeted therapy. The current study focuses on demonstrating the activity of MEK162
(binimetinib), a MEK inhibitor … strategies to enhance its therapeutic efficacy. MEK162 inhibits …

… We herein investigated the effects and pathways of MEK inhibitors, which inhibit the RAS–ERK
pathway, as a new molecular-targeted therapy for refractory neuroblastomas. …

… inhibition, may not be sufficient in themselves as a guide to the anticancer effects of MEK
inhibition… may influence the potential therapeutic outcomes of MEK inhibition in cancer patients: …

… narrow therapeutic index associated with MEK inhibition. … MEK is an important therapeutic
target, which can change clinical outcomes for patients with advanced cancer when inhibited …